Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
This antibody is a rat monoclonal antibody that binds specifically to mouse CX3CL1/Fractalkine, and it can neutralize the bioactivity of mouse CX3CL1/Fractalkine.
Recombinant Human Antibody (dAb HEL4) is capable of binding to Chicken LYZ, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-Chicken LYZ mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-Chicken LYZ mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. HEL4 is highly soluble at concentrations of> or =3 mM, essentially monomeric and resistant to aggregation upon thermodenaturation at concentrations as high as 56 microM.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
This antibody is a rat monoclonal antibody that binds specifically to mouse CX3CL1/Fractalkine, and it can neutralize the bioactivity of mouse CX3CL1/Fractalkine.
Recombinant Human Antibody (dAb HEL4) is capable of binding to Chicken LYZ, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-Chicken LYZ mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-Chicken LYZ mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. HEL4 is highly soluble at concentrations of> or =3 mM, essentially monomeric and resistant to aggregation upon thermodenaturation at concentrations as high as 56 microM.
Recombinant monoclonal antibody to CD70. VL-8-VH is a human antibody that can be potentially used in the treatment of autoimmune and inflammatory disease.
Untargeted metabolomics, namely discovery metabolomics, involves the comparison of the metabolome between the control and test groups, to identify differences between their metabolite profiles which may be relevant to specific biological conditions.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of IL2. under in vitro conditions, IL2-FuP efficiently initiated T-cell activation and stimulated LAKs as well as CTLs. Its potency was superior but not qualitatively different from that of a mixture of anti-EGFR and IL2 This immunocytokine was designed for treating Hodgkin's lymphoma.
MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers.
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts.
Provided is an anti-human CD40 antibody that is substantially antagonistic to a human CD40 antigen on the dendritic cell (DC) surface. And it is an agonistic anti-human CD40 antibody that is expected to have a therapeutic effect higher than those of conventional anti-human CD40 antibodies.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of TNF. TNF-FuP provided a weak stimulus for lymphocyte proliferation, but it had no effect on LAK cells. However, it supported activation of Mfs and, to a minor extent, of CTLs. This immunocytokine was designed for treating CD30-positive lymphoma.
The present antibody specifically binds to CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell- mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose.
Recombinant Chimeric (Human/Mouse) Antibody (CHI621) is capable of binding to CD25, expressed in Chinese Hamster Ovary cells (CHO). This chimeric antibody (SDZ CHI621) has been evaluated in a phase I/II clinical study in human renal cadaver transplantation and has shown very promising results.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to RLI. It was expressed in CHO and purified with affinity chromatography.
Recombinant Humanized monoclonal antibody expressed in CHO binding to Human CCL20. TAB-096CL is an investigational monoclonal antibody that is an antagonist for human CCL20, a chemokine ligand that binds to the CCR6 receptor. The CCL20/CCR6 interaction is implicated in a range of autoimmune diseases.
With unchallenged experience in diabody (Db) synthesis, Creative Biolabs has long been well-known in the field of antibody production. We elaborately integrate our multiple platforms for providing customer a desired Db with high affinity and low immunogenicity for both academic and clinical purposes.
Recombinant Anti-TNF & Anti-IL17A Bispecific Antibody (DVD-Ig).The DVD-Ig format that was used comprised a whole TNF-binding 'IgG' (with Fc region) to which additional variable regions that bind IL17A were fused 'on top' of the existing variable regions. The complex is capable of blocking TNF as well as IL17A simultaneously. bsAb-mediated simultaneous interference with two (or more) RTK signaling pathways, by inactivating either the RTKs or their ligand, should reduce the possibility of such escape mechanisms and, hence, improve therapeutic efficacyinhibiting their signaling and suppressing tumor cells growth. It was designed for the treatment of Plaque psoriasis.
The single plasma cell interrogation platform uses single cell-based screening of entire antibody-secreting B cell populations along with next-generation sequencing to retrieve native antibodies with extremely high in vivo specificity and affinity. During the native antibody development, the isolation and separation of single cells are the main technically challenging tasks. The yield and quality or in other words the integrity and purity of the cells as well as the throughput and the sensitivity of single cell isolation methods should be considered.
Subsequent library screening will fish out the antibody mutants that have high affinity. Two library screening strategies are available. In the first "surface-panning" strategy, decreasing concentrations of antigen is surface immobilized. In the second "solution-sorting" strategy, in which a labeled antigen in solution is used, we have two approaches, selection based on the equilibrium constant (Kd) and selection based on binding kinetics. In the first approach, sub-library phage is incubated with biotinylated antigen at controlled concentrations and bound phages are captured by immobilized NeutrAvidin. Selection based on binding kinetics is also termed off-rate (Koff) selection, in which phage population is allowed to saturate the labeled antigen before a large molar excess of unlabeled antigen is added to the mix for controlled periods of time. This allows the selection of mutant antibodies that have slower off-rates. Since a reduction in Koff usually results in a higher affinity, this selection approach singles out antibody variants with improved Kd.
We use an error-prone PCR integrated DNA-shuffling approach to mutate mainly CDR regions during sub-library construction. If the potential of introducing immunogenic mutations to framework positions is not a concern, we usually use this approach to create mutations at completely random positions across the entire VH and VL fragments. In these cases, the genetic diversity of the sub-library is further increased via passage through our proprietary bacterial mutator strain, CD-affi™.
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
Recombinant monoclonal antibody to CD70. VL-8-VH is a human antibody that can be potentially used in the treatment of autoimmune and inflammatory disease.
Untargeted metabolomics, namely discovery metabolomics, involves the comparison of the metabolome between the control and test groups, to identify differences between their metabolite profiles which may be relevant to specific biological conditions.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of IL2. under in vitro conditions, IL2-FuP efficiently initiated T-cell activation and stimulated LAKs as well as CTLs. Its potency was superior but not qualitatively different from that of a mixture of anti-EGFR and IL2 This immunocytokine was designed for treating Hodgkin's lymphoma.
MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers.
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts.
Provided is an anti-human CD40 antibody that is substantially antagonistic to a human CD40 antigen on the dendritic cell (DC) surface. And it is an agonistic anti-human CD40 antibody that is expected to have a therapeutic effect higher than those of conventional anti-human CD40 antibodies.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of TNF. TNF-FuP provided a weak stimulus for lymphocyte proliferation, but it had no effect on LAK cells. However, it supported activation of Mfs and, to a minor extent, of CTLs. This immunocytokine was designed for treating CD30-positive lymphoma.
The present antibody specifically binds to CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell- mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose.
Recombinant Chimeric (Human/Mouse) Antibody (CHI621) is capable of binding to CD25, expressed in Chinese Hamster Ovary cells (CHO). This chimeric antibody (SDZ CHI621) has been evaluated in a phase I/II clinical study in human renal cadaver transplantation and has shown very promising results.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to RLI. It was expressed in CHO and purified with affinity chromatography.
Recombinant Humanized monoclonal antibody expressed in CHO binding to Human CCL20. TAB-096CL is an investigational monoclonal antibody that is an antagonist for human CCL20, a chemokine ligand that binds to the CCR6 receptor. The CCL20/CCR6 interaction is implicated in a range of autoimmune diseases.
With unchallenged experience in diabody (Db) synthesis, Creative Biolabs has long been well-known in the field of antibody production. We elaborately integrate our multiple platforms for providing customer a desired Db with high affinity and low immunogenicity for both academic and clinical purposes.
Recombinant Anti-TNF & Anti-IL17A Bispecific Antibody (DVD-Ig).The DVD-Ig format that was used comprised a whole TNF-binding 'IgG' (with Fc region) to which additional variable regions that bind IL17A were fused 'on top' of the existing variable regions. The complex is capable of blocking TNF as well as IL17A simultaneously. bsAb-mediated simultaneous interference with two (or more) RTK signaling pathways, by inactivating either the RTKs or their ligand, should reduce the possibility of such escape mechanisms and, hence, improve therapeutic efficacyinhibiting their signaling and suppressing tumor cells growth. It was designed for the treatment of Plaque psoriasis.
The single plasma cell interrogation platform uses single cell-based screening of entire antibody-secreting B cell populations along with next-generation sequencing to retrieve native antibodies with extremely high in vivo specificity and affinity. During the native antibody development, the isolation and separation of single cells are the main technically challenging tasks. The yield and quality or in other words the integrity and purity of the cells as well as the throughput and the sensitivity of single cell isolation methods should be considered.
Subsequent library screening will fish out the antibody mutants that have high affinity. Two library screening strategies are available. In the first "surface-panning" strategy, decreasing concentrations of antigen is surface immobilized. In the second "solution-sorting" strategy, in which a labeled antigen in solution is used, we have two approaches, selection based on the equilibrium constant (Kd) and selection based on binding kinetics. In the first approach, sub-library phage is incubated with biotinylated antigen at controlled concentrations and bound phages are captured by immobilized NeutrAvidin. Selection based on binding kinetics is also termed off-rate (Koff) selection, in which phage population is allowed to saturate the labeled antigen before a large molar excess of unlabeled antigen is added to the mix for controlled periods of time. This allows the selection of mutant antibodies that have slower off-rates. Since a reduction in Koff usually results in a higher affinity, this selection approach singles out antibody variants with improved Kd.
We use an error-prone PCR integrated DNA-shuffling approach to mutate mainly CDR regions during sub-library construction. If the potential of introducing immunogenic mutations to framework positions is not a concern, we usually use this approach to create mutations at completely random positions across the entire VH and VL fragments. In these cases, the genetic diversity of the sub-library is further increased via passage through our proprietary bacterial mutator strain, CD-affi™.
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
1. cgrp antibody
• Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-
terminal epitope with F37 and G33 being the most important residues.
G1 does not bind to CGRP when an extra amino acid residue (alanine)
is added at the C-terminal.